STERIS price to book ratio STE
Market value divided by the book value of the company's net assets, since 2019.
- Today, Oct 23, 2026
- 3.1×
- 7-year median
- 3.5×
- Against its 7-year history
- 16th
- percentile: 0 is its lowest day, 100 its highest
- 7-year range
- 2.5× to 4.8×
- Peer median
- 3.8×
STERIS' price to book ratio is 3.1× as of Oct 23, 2026.
That is below its 7-year median of 3.5×, lower than on 84% of days in the last 7 years.
Over that time it ranged from 2.5× in Nov 2022 to 4.8× in Jul 2021.
The median for 10 healthcare stocks of a similar size is 3.8×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 3.1× | 2.8× | 3.8× |
| 2025 | 3.6× | 3.1× | 3.9× |
| 2024 | 3.1× | 3.1× | 3.8× |
| 2023 | 3.5× | 2.9× | 3.8× |
| 2022 | 3.2× | 2.5× | 3.8× |
| 2021 | 3.7× | 3.1× | 4.8× |
| 2020 | 4.4× | 2.9× | 4.6× |
| 2019 | 4.0× | 3.6× | 4.1× |
Against its peers
Companies in Healthcare nearest STERIS' size, closest first, today.
| Company | Price to book ratio |
|---|---|
| STESTERIS | 3.1× |
| INCYIncyte | 3.7× |
| THCTenet Healthcare | 4.6× |
| UTHRUnited Therapeutics | 3.9× |
| LHLabcorp | 3.1× |
| DGXQuest Diagnostics | 3.6× |
| ZBHZimmer Biomet | 1.5× |
| MEDPMedpace | 43.1× |
| WSTWest Pharmaceutical Services | 9.2× |
| RVTYRevvity | 2.5× |
| DXCMDexCom | 11.2× |
| Peer median | 3.8× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on STERIS
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.